Total Payments
$14,454
2019 Payments
$101.09
Companies
7
Transactions
44
Payment Breakdown by Category
Travel$7,891 (54.6%)
Research$4,993 (34.5%)
Food & Beverage$1,571 (10.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $7,891 | 16 | 54.6% |
| Unspecified | $4,993 | 5 | 34.5% |
| Food and Beverage | $1,571 | 23 | 10.9% |
Payments by Type
General
$9,462
39 transactions
Research
$4,993
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $5,001 | 9 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,179 | 5 | $0 (2018) |
| Eli Lilly and Company | $1,942 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,783 | 11 | $0 (2017) |
| AMAG Pharmaceuticals, Inc. | $1,191 | 5 | $0 (2017) |
| Allergan Inc. | $1,138 | 11 | $0 (2018) |
| Alkermes, Inc. | $220.41 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $101.09 | 1 | Alkermes, Inc. ($101.09) |
| 2018 | $4,436 | 17 | Takeda Pharmaceuticals U.S.A., Inc. ($3,179) |
| 2017 | $9,917 | 26 | Janssen Research & Development, LLC ($5,001) |
All Payment Transactions
44 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/26/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $101.09 | General |
| Category: CNS | ||||||
| 09/29/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $420.40 | General |
| 09/29/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $190.87 | General |
| 09/29/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $112.91 | General |
| 09/29/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $47.44 | General |
| 09/29/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $18.39 | General |
| 09/27/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $144.36 | General |
| 09/27/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $74.62 | General |
| 09/27/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 09/27/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $41.62 | General |
| 09/27/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $19.21 | General |
| 09/27/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $18.34 | General |
| 09/12/2018 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $119.32 | General |
| Category: CNS | ||||||
| 07/24/2018 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $128.69 | General |
| 05/01/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Actos (Drug) | — | In-kind items and services | $585.80 | Research |
| Study: Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD • Category: Diabetes | ||||||
| 04/01/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Actos (Drug) | — | In-kind items and services | $1,212.00 | Research |
| Study: Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD • Category: Diabetes | ||||||
| 03/31/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Actos (Drug) | — | In-kind items and services | $242.40 | Research |
| Study: Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD • Category: Diabetes | ||||||
| 02/28/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Actos (Drug) | — | In-kind items and services | $1,010.00 | Research |
| Study: Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD • Category: Diabetes | ||||||
| 08/26/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Travel and Lodging | Cash or cash equivalent | $887.28 | General |
| Category: INTRAROSA | ||||||
| 08/26/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Food and Beverage | Cash or cash equivalent | $41.00 | General |
| Category: INTRAROSA | ||||||
| 08/26/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Food and Beverage | Cash or cash equivalent | $40.00 | General |
| Category: INTRAROSA | ||||||
| 08/25/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Travel and Lodging | Cash or cash equivalent | $137.30 | General |
| Category: INTRAROSA | ||||||
| 08/25/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Food and Beverage | Cash or cash equivalent | $85.00 | General |
| Category: INTRAROSA | ||||||
| 06/08/2017 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $525.00 | General |
| 06/08/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $204.75 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Pharmaceuticals U.S.A., Inc. | $3,050 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $1,942 | 1 |
About Dr. Anne Koplin, MD
Dr. Anne Koplin, MD is a Psychiatry healthcare provider based in Madison, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457444374.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anne Koplin, MD has received a total of $14,454 in payments from pharmaceutical and medical device companies, with $101.09 received in 2019. These payments were reported across 44 transactions from 7 companies. The most common payment nature is "Travel and Lodging" ($7,891).
Ad
Practice Information
- Specialty Psychiatry
- Location Madison, WI
- Active Since 10/02/2006
- Last Updated 04/13/2022
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1457444374
Products in Payments
- Actos (Drug) $3,050
- INTRAROSA (Drug) $1,191
- CNP520 (Drug) $971.52
- Aristada 441 mg (Drug) $119.32
- ARISTADA (Drug) $101.09
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Madison
David Plante, Md, MD
Psychiatry — Payments: $118,445
Psychiatry $118,445
Dr. Sobia Kirmani Moe, M.d, M.D
Psychiatry — Payments: $60,165
Psychiatry $60,165
Kenneth Herrmann, Md, MD
Psychiatry — Payments: $60,047
Psychiatry $60,047
Ned Kalin, Md, MD
Psychiatry — Payments: $47,050
Psychiatry $47,050
Charles Raison, M.d, M.D
Psychiatry — Payments: $36,164
Psychiatry $36,164
Anika Wilson, Md, MD
Psychiatry — Payments: $34,601
Psychiatry $34,601